Ionis Pharmaceuticals, Inc.

This study tested the long-term safety and effectiveness of donidalorsen, an injectable drug, in 20 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received different doses over 64 weeks. The main goal was to check f…

This study tested a drug called olezarsen in 154 adults with high triglycerides (a type of blood fat) and either heart disease or very high triglycerides. Participants received injections of the drug or a placebo for up to 12 months. The main goal was to see if the drug could low…

This Phase 3 study tested a drug called olezarsen in 1,478 people with very high triglycerides (a type of blood fat) and either heart disease or a high risk for it. Participants received either olezarsen or a placebo as a shot under the skin. The main goal was to see if olezarsen…

This Phase 3 trial tested a drug called olezarsen in 617 people with severe hypertriglyceridemia (very high blood fats). Participants received either the drug or a placebo as a shot under the skin. The main goal was to see if olezarsen could lower triglyceride levels more than pl…

This study tested a new medicine called olezarsen in 446 people with very high levels of blood fats (triglycerides). The goal was to see if it could lower these fats more than a placebo. Participants received shots under the skin and followed a healthy diet.

This early-stage trial tested the safety of a new drug called BIIB094 in 62 adults with Parkinson's disease. The drug was given as a spinal injection to see if it is safe and how the body processes it. The study included people with and without certain genetic variations. Results…